At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Catherine M. Bollard, MBChB, MD, FRACP, FRCPA, of Children’s National Health System and The George Washington University, Washington, DC, chairs a discussion with Wyndham Wilson, MD, PhD, of the National Cancer Institute, Bethesda, MD, Louis M. Staudt, MD, PhD, of the National Cancer Institute, Bethesda, MD, and Riccardo Dalla-Favera, MD, of the Institute of Cancer Genetics, Columbia University, New York, NY, on the clinical implications of the current understanding of the biology of B cells and diffuse large B-cell lymphoma (DLBCL) subtypes, including activated B-cell-like (ABC) DLBCL and germinal-center B-cell-like (GCB) DLBCL. They explain that these subtypes are characterised by significant differences in outcomes and responses to treatment.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates